About this trial
This study is a Phase 1/2, open-label study to investigate the safety and tolerability, efficacy, pharmacokinetics, and immunogenicity of Modakafusp Alfa (TAK-573) as a single agent in patients with relapsed refractory multiple myeloma
Patient Profile
The target population for this study are patients with relapsed refractory multiple myeloma
Where’s this trial being run?
Cork University Hospital, St James’s Hospital, and St Vincents University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | TAK-573-1501 |
|---|---|
| Number: | 22-14 |
| Full Title: | A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma |
| Principal Investigator: | Dr Kamal Fadalla |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Takeda |
| Recruitment Started: |
Global: TBC Ireland: TBC |
| Global Recruitment Target: | 236 |
|---|---|
| Ireland Recruitment Target: | TBC |